Cat. No. 4670
Chemical Name: 2,6-Dichloro-N-[4-chloro-3-[2-(dime
Biological ActivityUrotensin-II (UT) antagonist. Inhibits urotensin-II-induced proliferation of neonatal cardiac fibroblasts. Attenuates cardiac dysfunction in a rat model of coronary artery ligation; decreases cardiomyocyte hypertrophy, ventricular dilatation and cardiac remodeling.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Papadopoulos et al (2008) Urotensin-II and cardiovascular remodeling. Peptides 29 764. PMID: 17988761.
Bousette et al (2006) Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 2919. PMID: 16919371.
Bousette et al (2006) Urotensin-II blockade with SB-611812 attenutes cardiac dysfunction in a rat model of coronary artery ligation. J.Mol.Cell Cardiol. 41 285. PMID: 16797584.
If you know of a relevant reference for SB 611812 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SB 611812 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: SB 611812, supplier, SB611812, GSK, urotensin-II, urotensin, receptors, antagonists, cardiac, dysfunction, remodeling, remodelling, Tocris Bioscience, Urotensin-II Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailableML 233
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorption
June 14 - 17, 2017
Boston, MA, USA